BridgeBio Pharma Inc (NASDAQ: BBIO)’s stock price has gone decline by -2.61 in comparison to its previous close of 25.66, however, the company has experienced a 3.05% increase in its stock price over the last five trading days. globenewswire.com reported 2024-08-19 that PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics, the BridgeBio affiliate focused on developing treatment options for skeletal dysplasias, today announced the launch of the initial phase of MyAchonJourney, a new online resource to support individuals and families living with achondroplasia.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
BBIO has 36-month beta value of 1.07. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BBIO is 140.74M, and currently, short sellers hold a 14.18% ratio of that float. The average trading volume of BBIO on August 21, 2024 was 1.87M shares.
BBIO’s Market Performance
The stock of BridgeBio Pharma Inc (BBIO) has seen a 3.05% increase in the past week, with a -9.09% drop in the past month, and a -14.65% fall in the past quarter. The volatility ratio for the week is 4.41%, and the volatility levels for the past 30 days are at 4.72% for BBIO. The simple moving average for the past 20 days is -1.27% for BBIO’s stock, with a -17.20% simple moving average for the past 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Raymond James repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Raymond James is $45 based on the research report published on March 21, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $37. The rating they have provided for BBIO stocks is “Market Perform” according to the report published on January 31st, 2024.
Wells Fargo gave a rating of “Overweight” to BBIO, setting the target price at $58 in the report published on December 08th of the previous year.
BBIO Trading at -3.99% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.61% of loss for the given period.
Volatility was left at 4.72%, however, over the last 30 days, the volatility rate increased by 4.41%, as shares sank -4.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.91% lower at present.
During the last 5 trading sessions, BBIO rose by +3.39%, which changed the moving average for the period of 200-days by -6.87% in comparison to the 20-day moving average, which settled at $25.25. In addition, BridgeBio Pharma Inc saw -38.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 27,389 shares at the price of $24.69 back on Aug 19 ’24. After this action, Kumar Neil now owns 4,897,443 shares of BridgeBio Pharma Inc, valued at $676,256 using the latest closing price.
STEPHENSON BRIAN C, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc, sale 4,155 shares at $24.69 during a trade that took place back on Aug 19 ’24, which means that STEPHENSON BRIAN C is holding 85,192 shares at $102,590 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.3 for the present operating margin
- 0.98 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.07. The total capital return value is set at -0.76.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 2.74 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at -1.58. The interest coverage ratio of the stock is -1016.16.
Currently, EBITDA for the company is -574.64 million with net debt to EBITDA at -2.4. When we switch over and look at the enterprise to sales, we see a ratio of 26.96. The receivables turnover for the company is 332.01for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
To put it simply, BridgeBio Pharma Inc (BBIO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
